BridgeBio price target raised to $114 from $100 at Bernstein

Bernstein raised the firm’s price target on BridgeBio (BBIO) to $114 from $100 and keeps an Outperform rating on the shares. The firm notes Attruby U.S. product sales of $181M beat consensus by 5%, while EPS missed by 25% due to nonoperating expenses. Given strong Attruby KPIs, Bernstein increased its Q2 and FY26 estimates to $212M and $900M, respectively. The firm is also raising Attruby peak sales to $2.85B based on the tafamidis IP resolution.